Engineering Better Cell Therapies for Cancers - Triumvira Immunologics | Engineered T Cell Therapies
Cell Therapies in Cancer Treatment
Cell therapies are revolutionizing the way cancers are treated, but existing cell therapies have their limits. They have been more successful at treating hematologic tumors than solid tumors, and they can sometimes cause serious side effects, such as the destruction of antibodies or what’s known as cytokine storms in which the immune system gets over-revved and attacks healthy cells. Triumvira Immunologics is developing autologous and allogeneic T-Cell therapies that it believes can address the limitations of existing cell therapies and be used to treat both liquid and solid tumors.
We spoke to Paul Lammers, CEO of Triumvira, about the company’s platform technology, why it’s robust and versatile, and why its lead indication is for cancer where effective treatments already exist.
[Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors](/content/preclinical-characterization-of-allogeneic-her2-tac-t-cells-for-the-treatment-of-her2-positive-solid-tumors/ "Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors"/index.html)
[First in Human Episode #25 featuring Dr. Paul Lammers](/content/first-in-human-episode-25-featuring-dr-paul-lammers/ "First in Human Episode #25 featuring Dr. Paul Lammers"/index.html)